Literature DB >> 22330966

American Joint Committee on Cancer T category for eyelid sebaceous carcinoma correlates with nodal metastasis and survival.

Bita Esmaeli1, Qasiem J Nasser, Hilda Cruz, Melissa Fellman, Carla L Warneke, Doina Ivan.   

Abstract

PURPOSE: To determine whether T category of the American Joint Committee on Cancer (AJCC) TNM staging system for eyelid carcinoma, 7th edition, correlates with lymph node metastasis, distant metastasis, and survival in patients with sebaceous carcinoma of the eyelid.
DESIGN: Retrospective, cohort study. PARTICIPANTS: Fifty consecutive patients treated by 1 author (BE) for eyelid sebaceous carcinoma between May 1999 and August 2010.
METHODS: Each tumor was staged according to the AJCC 7th edition TNM criteria. The Kaplan-Meier method was used to determine associations between disease-specific survival and (1) T category at presentation, (2) lymph node metastasis, and (3) distant metastasis. MAIN OUTCOME MEASURES: T category at presentation, nodal metastasis, survival.
RESULTS: The study included 37 women and 13 men (median age, 68.5 years; range, 44-86 years). Forty-four patients were white, 5 were Hispanic, and 1 was Asian. TNM designations were TXN0M0, 7 patients; T1N0M0, 4 patients; T2aN0M0, 12 patients; T2bN0M0, 11 patients; T2bN1M0, 2 patients; T2bN1M1, 1 patient; T3aN0M0, 2 patients; T3aN1M0, 5 patients; T3bN0M0, 1 patient; T3bN1M0, 1 patient; T3bN0M1, 2 patients; T4N0M0, 1 patient; and T4N0M1, 1 patient. T category at presentation was significantly associated with lymph node metastasis (P = 0.0079). No tumors with T category better than T2b or smaller than 9 mm in greatest dimension were associated with nodal metastasis. Five patients (10%) died of disease during follow-up. Their TNM designations were T2bN1M1, 1 patient; T3bN0M1, 2 patients; T4N0M0, 1 patient; and T4N0M1, 1 patient. No tumors smaller than 12 mm in greatest dimension were associated with distant metastasis or death. T category was significantly associated with disease-specific survival (P = 0.0009). Disease-specific survival was poorer among patients with T category of T3a or worse (P = 0.035).
CONCLUSIONS: T category in the 7th edition of the AJCC TNM staging system for eyelid carcinoma correlates with outcomes in patients with sebaceous carcinoma of eyelid. On the basis of the present findings, it seems reasonable to recommend sentinel lymph node biopsy or at least strict regional lymph node surveillance for patients with eyelid sebaceous carcinoma with tumors of T category T2b or worse or 10 mm or more in greatest dimension.
Copyright © 2012 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22330966      PMCID: PMC3869195          DOI: 10.1016/j.ophtha.2011.11.006

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  16 in total

Review 1.  Sebaceous carcinoma of the ocular region: a review.

Authors:  Jerry A Shields; Hakan Demirci; Brian P Marr; Ralph C Eagle; Carol L Shields
Journal:  Surv Ophthalmol       Date:  2005 Mar-Apr       Impact factor: 6.048

2.  Histopathological review of sebaceous carcinoma of the eyelid.

Authors:  Patricia Rusa Pereira; Alexandre Nakao Odashiro; Abelardo A Rodrigues-Reyes; Zelia Maria S Correa; João Pessoa de Souza Filho; Miguel N Burnier
Journal:  J Cutan Pathol       Date:  2005-08       Impact factor: 1.587

3.  Sebaceous carcinoma of the eyelid, eyebrow, caruncle, and orbit.

Authors:  M Boniuk; L E Zimmerman
Journal:  Trans Am Acad Ophthalmol Otolaryngol       Date:  1968 Jul-Aug

4.  Sebaceous cell carcinomas of the ocular adnexa.

Authors:  C Ni; S S Searl; P K Kuo; F R Chu; C S Chong; D M Albert
Journal:  Int Ophthalmol Clin       Date:  1982

5.  Outcome of patients with periocular sebaceous gland carcinoma with and without conjunctival intraepithelial invasion.

Authors:  A N Chao; C L Shields; H Krema; J A Shields
Journal:  Ophthalmology       Date:  2001-10       Impact factor: 12.079

6.  Positive sentinel node in sebaceous carcinoma of the eyelid.

Authors:  Aaron Savar; Patrick Oellers; Jeffrey Myers; Victor G Prieto; Carlos Torres-Cabala; Steven J Frank; Doina Ivan; Bita Esmaeli
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2011 Jan-Feb       Impact factor: 1.746

7.  Treatment and outcomes for metastatic sebaceous cell carcinoma of the eyelid.

Authors:  Amina Husain; George Blumenschein; Bita Esmaeli
Journal:  Int J Dermatol       Date:  2008-03       Impact factor: 2.736

8.  Sebaceous cell carcinoma of the ocular adnexa: clinical presentations, histopathology, and outcomes.

Authors:  Alice Song; Keith D Carter; Nasreen A Syed; Julia Song; Jeffrey A Nerad
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2008 May-Jun       Impact factor: 1.746

9.  Introduction of the 7th edition eyelid carcinoma classification system from the American Joint Committee on Cancer-International Union Against Cancer staging manual.

Authors:  Darryl J Ainbinder; Bita Esmaeli; Stephen C Groo; Paul T Finger; Joseph P Brooks
Journal:  Arch Pathol Lab Med       Date:  2009-08       Impact factor: 5.534

10.  Improved survival rates in sebaceous carcinoma of the eyelid.

Authors:  M M K Muqit; F Roberts; W R Lee; E Kemp
Journal:  Eye (Lond)       Date:  2004-01       Impact factor: 3.775

View more
  23 in total

1.  Prognostic value of clinical and pathologic T stages defined by the American Joint Committee on Cancer for eyelid sebaceous carcinoma in Korea.

Authors:  Youn Joo Choi; Hyun Chul Jin; Min Joung Lee; Namju Kim; Ho-Kyung Choung; Sang In Khwarg
Journal:  Jpn J Ophthalmol       Date:  2014-04-25       Impact factor: 2.447

Review 2.  Surgical Management of Periocular Cancers: High- and Low-Risk Features Drive Treatment.

Authors:  Richard C Allen
Journal:  Curr Oncol Rep       Date:  2017-09       Impact factor: 5.075

Review 3.  [Therapy options for malignant eyelid tumors].

Authors:  M Weiling; A Bergua; F E Kruse; L Holbach
Journal:  Ophthalmologe       Date:  2016-12       Impact factor: 1.059

4.  CDKN2A, CDK1, and CCNE1 overexpression in sebaceous gland carcinoma of eyelid.

Authors:  Tatsuya Yunoki; Tetsushi Hirano; Yoshiaki Tabuchi; Yukihiro Furusawa; Misako Torigoe; Takahiko Nakajima; Johji Imura; Atsushi Hayashi
Journal:  Int Ophthalmol       Date:  2019-09-30       Impact factor: 2.031

5.  Eyelid sebaceous carcinoma: Validation of the 8th edition of the American Joint Committee on cancer T staging system and the prognostic factors for local recurrence, nodal metastasis, and survival.

Authors:  Yun Hsia; Ching-Yuan Yeh; Yi-Hsuan Wei; Lily-Wei Chen; Shu-Lang Liao
Journal:  Eye (Lond)       Date:  2019-05-31       Impact factor: 3.775

Review 6.  Sentinel lymph node biopsy for eyelid and conjunctival tumors: what is the evidence?

Authors:  Pia R Mendoza; Hans E Grossniklaus
Journal:  Int Ophthalmol Clin       Date:  2015

Review 7.  Sebaceous Carcinoma: A Review of the Scientific Literature.

Authors:  Thomas Knackstedt; Faramarz H Samie
Journal:  Curr Treat Options Oncol       Date:  2017-08

8.  The practice patterns in the management of sebaceous carcinoma of the eyelid in the Asia Pacific region.

Authors:  Janice J C Cheung; Bita Esmaeli; Stacey C Lam; Tracey Kwok; Hunter K L Yuen
Journal:  Eye (Lond)       Date:  2019-04-05       Impact factor: 3.775

9.  Prognosis of eyelid sebaceous gland carcinoma based on the tumor (T) category of the American Joint Committee on Cancer (AJCC) classification.

Authors:  Swathi Kaliki; Adit Gupta; Mohammed Hasnat Ali; Anuradha Ayyar; Milind N Naik
Journal:  Int Ophthalmol       Date:  2016-02-01       Impact factor: 2.031

10.  Periocular sebaceous gland carcinoma: A comprehensive review.

Authors:  Kaustubh Mulay; Ekta Aggarwal; Valerie A White
Journal:  Saudi J Ophthalmol       Date:  2013-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.